publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
Other/Multi
A retrospective study of do-not-do practice recommendations in metastatic breast cancer in Spain
Edoxaban
Pharmacokinetics of edoxaban 15 mg in very elderly patients with nonvalvular atrial fibrillation: A subanalysis of the ELDERCARE-AF study
Edoxaban
Venous thromboembolism in Japanese patients with breast cancer: Subgroup analysis of the Cancer-VTE registry
Other/Multi
Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany
T-DXd
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
Edoxaban
Impact of frailty in patients with non-valvular atrial fibrillation undergoing catheter ablation
Pexidartinib
Real-world patient experience of pexidartinib for tenosynovial giant-cell tumor
Other/Multi
Augmenting external control arms using Bayesian borrowing: A case study in first-line non-small cell lung cancer
Valemetostat
Effective in vitro evaluation of the risk of histamine release related to valemetostat tosylate using MRGPRX2-expressing cells